A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma.

Trial Profile

A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2013

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate
  • Indications Asthma
  • Focus Adverse reactions; Pharmacogenomic; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Feb 2013 Planned number of patients changed from 500 to 503 as reported by European Clinical Trials Database record.
    • 19 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top